DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL
“Throughout the history of tumor infiltrating lymphocyte therapy, certain patients with melanoma and several other solid tumor types have experienced extraordinarily durable tumor responses,” said
As a key step toward advancing DeTIL-0255 into the clinic, Nurix performed a series of experiments on human tumors to characterize the effects of CBL-B inhibition using NX-0255 on the production and quality of TIL. Tumor samples were obtained from 16 patients with ovary, colon, lung, head and neck, breast, or vulva carcinomas. Tumors from patients were cultured either in the presence of recombinant human IL-2 (rhIL-2) alone to generate TIL or in combination with NX-0255 + rhIL-2 to generate DeTIL-0255, Nurix’s cell therapy clinical candidate. Compared to TIL, DeTIL-0255 demonstrated:
- Increased T cell expansion (p<0.001);
- Reduced expression of markers associated with T cell exhaustion such as PD-1, LAG-3 and TIM-3 (p<0.05);
- Increased cytotoxicity as measured by increased perforin, granzyme B, and the degranulation marker CD107a (p<0.001);
- Increased 4-1BB, a surrogate marker of tumor reactivity (p<0.05); and
- Increased T cell receptor diversity (p<0.05)
Taken together, these findings support advancing DeTIL-0255 into human clinical trials as a potentially superior, drug-enhanced TIL product candidate.
Nurix’s cell therapy programs are headed by
“We are extremely proud of Michael and thank SITC for recognizing his achievements in the field of immunotherapy for cancer that span many of the critical advances that have had a major impact on the field,” said
Presentation Details
- Conference:
Society for Immunotherapy of Cancer Annual Meeting - Title: NX-0255, a Small-Molecule CBL-B Inhibitor, Expands and Enhances Tumor-Infiltrating Lymphocytes for Use in Adoptive Cancer Immunotherapy
- Abstract number: 98
- Date:
November 13, 2021 - Presenter:
Sarah Whelan , Ph.D.
About DeTIL-0255
Nurix’s lead cell therapy candidate, DeTIL-0255, is an autologous cell therapy consisting of T cells derived from a patient’s tumor expanded in culture with NX-0255 and rhIL-2. DeTIL-0255 is designed to be a single administration autologous TIL therapy infused following non-myeloablative chemotherapy. Based on its preclinical characterization, Nurix believes DeTIL-0255 could allow a broader application of TIL therapy. Nurix is currently working to initiate a Phase 1 trial of DeTIL-0255 at multiple sites in
About
About
Forward Looking Statement
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of our clinical trial programs for our drug candidates, preclinical activities, research and development costs, current and prospective collaborations; the potential advantages of our DELigase® platform and drug candidates; the extent to which our scientific approach and DELigase® platform may potentially address a broad range of diseases; the estimated size of the market for our drug candidates; and the timing and success of the development and commercialization of our anticipated drug candidates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions regarding the future of Nurix’s business, future plans and strategies, its development plans, its preclinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix’s ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of preclinical and clinical trials; (iii) Nurix’s ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (v) Nurix’s ability to protect intellectual property and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Annual Report on Form 10-K filed with the
Contacts:
Investors: | Media: |
jkantor@nurixtx.com | lwolffe@wheelhouselsa.com |
Source:
2021 GlobeNewswire, Inc., source